Furthermore, a β1-selective antagonist, metoprolol, also inhibited adult CCM suggesting that β1AR-specific antagonists may be useful for CCM treatment and will carry less potential for β2 AR-related side effects such as bronchospasm (Maclagan and Ney, 1979). The gene discussed is ADRB1; the disease is cerebral cavernous malformation.